TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23889096
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of benazepril (0.45 mg/kg daily for 4 days)
Study: 21742089
Drug: Routine PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine PCI with standard-of-care medical therapy
Study: 12074359
Drug: Omapatrilat (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (40 mg)
Study: 8924548
Drug: Theophylline 300
Normalized name: theophylline 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 300 mg twice a day (E1)
Study: 8924548
Drug: Salbutamol 4
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 4 mg tid (E2)
Study: 8924548
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Theophylline 200 mg and Salbutamol 4 mg (E3)
Study: 8924548
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Theophylline 100 mg and Salbutamol 2 mg (E4)
Study: 8924548
Drug: Placebo calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo calcium lactate 300 mg tid (E5)
Study: 27932240
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream once daily (superficial basal cell carcinoma, 6 weeks; nodular basal cell carcinoma, 12 weeks)
Study: 27932240
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream once daily
Study: 25216962
Drug: EMLA patches
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA patches on all abdominal incisions
Study: 25216962
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches on all abdominal incisions
Study: 12586130
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR 2.8-4.2)
Study: 18474393
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg/d and Warfarin (INR 2.0-2.5)
Study: 23130135
Drug: Aspirin 160
Normalized name: aspirin 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 160 mg/d
Study: 11795688
Drug: cream with
Normalized name: CREAM WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream with phytoestrogens
Study: 11795688
Drug: placebo (cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (cold cream)
Study: 9709785
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation (285.6 mg of elemental iron/day)
Study: 9709785
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron plus intravenous iron supplementation (285.6 mg of elemental iron/day orally plus 102.5 mg of elemental iron/week intravenously)
Study: 8071390
Drug: 600‐mg methocel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600‐mg methocel tablet (sustained-release)
Study: 8071390
Drug: 300‐mg CAP/carbovax-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300‐mg CAP/carbovax-coated tablet (immediate-release)
Study: 8071390
Drug: 600‐mg sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600‐mg sustained-release tablet
Study: 8071390
Drug: 300‐mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300‐mg tablet b.i.d.
Study: 29766748
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) enriched 5% oil formulation with 0.25% δ‐9‐tetrahydrocannabinol (THC) 20:1
Study: 29766748
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) enriched 5% oil formulation with 0.83% THC 6:1
Study: 26617135
Drug: Parenteral Nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral Nutritional Support (PN)
Study: 18787350
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel at a dose of 100 mg/m(2) plus radiotherapy (group I)
Study: 16969042
Drug: Gemcitabine; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine; specific dosage and duration not mentioned
Study: 10218338
Drug: Surfactant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant therapy using the INSURE approach (Intubation‐SURfactant‐Extubation)
Study: 2006722
Drug: Propofol 10
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 10 mg kg‐1 h‐1
Study: 6216344
Drug: Piperacillin (181
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (181 mg/kg intravenous daily for 6 days)
Study: 6216344
Drug: Carbenicillin (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenicillin (270 mg/kg intravenous daily for 6 days)
Study: 17575485
Drug: Granisetron injection
Normalized name: granisetron Injection
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron injection
Study: 14752215
Drug: Butterbur root
Normalized name: butterbur root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butterbur root extract (Petadolex), 25 mg, two capsules twice a day
Study: 11822760
Drug: Nolatrexed 725
Normalized name: Nolatrexed
DrugBank: Nolatrexed (DB12912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nolatrexed 725 mg/m2 per day (5-day continuous infusion every three weeks)
Study: 11822760
Drug: Methotrexate 40
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 40 mg/m2 weekly (short infusion)
Study: 8209058
Drug: Capsaicin inhalation
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin inhalation (3.33 x 10(‐4) M)
Study: 27494094
Drug: Neck-specific training
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck-specific training in combination with a cognitive behavioural approach
Study: 25282031
Drug: CoQ10 100
Normalized name: Walgreens CoQ10 100mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 100 mg 3 times daily
Study: 19607755
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nefazodone and Cognitive Behavioral Analysis System of Psychotherapy
Study: 16477764
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (200 mg daily for 15 months)
Study: 12189442
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion (3 g in 10 ml saline)
Study: 1955626
Drug: 12 tablets
Normalized name: nylon 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 tablets of the supplement a day for three menstrual cycles
Study: 1955626
Drug: 6 tablets
Normalized name: ALLANTOIN 66 mg in 600 mg VAGINAL TABLET [Jilgyungyi (6 Tablets)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 tablets of the supplement a day for three menstrual cycles
Study: 23026843
Drug: Clopidogrel besylate
Normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel besylate 75 mg
Study: 17899308
Drug: Cevimeline hydrochloride
Normalized name: Cevimeline Hydrochloride
DrugBank: Cevimeline (DB00185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cevimeline hydrochloride 30 mg three times per day for 10 weeks
Study: 16871247
Drug: Fosinopril 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 5 mg titrated to 20 mg daily
Study: 10937676
Drug: Tamoxifen (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (higher doses proposed, at least four to eight-fold that of the dose efficacious in an oestrogen-receptor dependent mechanism)
Study: 1431597
Drug: Psyllium (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (15 g/day for 40 days)
Study: 3883690
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel (Prostaglandin E2)
Study: 30368585
Drug: BNC105P 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNC105P 12 mg/m2 with gemcitabine 1000 mg/m2 and carboplatin AUC4
Study: 30368585
Drug: BNC105P 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNC105P 16 mg/m2 (maintenance treatment)
Study: 30368585
Drug: BNC105P 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNC105P 800 mg/m2 with gemcitabine and carboplatin AUC4
Study: 30368585
Drug: BNC105P 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNC105P 1000 mg/m2 with gemcitabine and carboplatin AUC4
Study: 29359856
Drug: Flumazenil injection
Normalized name: Flumazenil Injection
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil injection administered i.v. 10 min after transfer to recovery room
Study: 29359856
Drug: Flumazenil injection
Normalized name: Flumazenil Injection
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil injection
Study: 24925094
Drug: True needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: True needle acupuncture for ten treatments over eight weeks
Study: 24925094
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture with non‐insertive (blunt) needles for ten treatments over eight weeks
Study: 23101480
Drug: Rituximab in
Normalized name: rituximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab in addition to standard treatment with steroid-boli
Study: 23101480
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (placebo)
Study: 19701637
Drug: Tocilizumab, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab, administered in a clinical setting, dosage not specified, duration of treatment not specified.
Study: 17681004
Drug: Gaviscon Advance
Normalized name: Gaviscon
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaviscon Advance (10 ml)
Study: 17681004
Drug: New tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: New tablet product containing the same active ingredients as Gaviscon Advance
Study: 17681004
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 ml water)
Study: 9682114
Drug: Heparin-surface-modified (HSM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-surface-modified (HSM) convex-plano laser-ridge IOL
Study: 2113492
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a) and hMG; 38 cycles
Study: 360842
Drug: Clotrimazole 1
Normalized name: clotrimazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 1 per cent vaginal cream for 7 days
Study: 360842
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate 2 per cent vaginal cream for 14 days
Study: 29178758
Drug: Mg(OH)2 dentifrice
Normalized name: Magnesium, ion(Mg2+)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg(OH)2 dentifrice
Study: 17296460
Drug: Imidapril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril (up to 20 mg/d)
Study: 17296460
Drug: Candesartan (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (up to 16 mg/d)
Study: 8544215
Drug: Oral suspension
Normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral suspension of antibiotic-resistant Bifidobacterium longum for 30 days, commencing 10-12 days post-irradiation.
Study: 1830860
Drug: Nicotinamide (oral)
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide (oral)
Study: 6228933
Drug: Hydergine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergine treatment
Study: 15213636
Drug: Gacyclidine 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gacyclidine 0.02 mg/kg
Study: 15213636
Drug: Gacyclidine 0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gacyclidine 0.005 mg/kg
Study: 15213636
Drug: Gacyclidine 0.001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gacyclidine 0.001 mg/kg
Study: 2664089
Drug: Levodopa (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (mean dose 444 mg daily)
Study: 2664089
Drug: Bromocriptine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (mean dose 50 mg daily)
Study: 918999
Drug: Chemotherapy prior
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy prior to radiotherapy
Study: 918999
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with a focal dose of 3000 rd within three weeks
Study: 29156619
Drug: Calorie-dense and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie-dense and protein-rich early enteral nutrition (1300 Kcal/L and 66.7 g/L protein)
Study: 29156619
Drug: Standard isocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard isocaloric early enteral nutrition (1000 Kcal/L and 38 g/L protein)
Study: 25907158
Drug: Idebenone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone (300 mg three times a day)
Study: 19242030
Drug: Tepid sponging
Normalized name: spongia tosta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepid sponging and antipyretic drug (Paracetamol) (n=73)
Study: 19242030
Drug: Only antipyretic
Normalized name: ANTIPYRETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only antipyretic drug (Paracetamol) (n=77)
Study: 11717609
Drug: Culture-guided antibiotics
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture-guided antibiotics for treatment
Study: 30839402
Drug: Huperzine-A treatment
Normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine-A treatment for 8 weeks
Study: 26179113
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (3 g/day) with low-calorie diet
Study: 26179113
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 g/day) with low-calorie diet
Study: 23388213
Drug: Active cardiac
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active cardiac resynchronization therapy
Study: 23388213
Drug: Inactive cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive cardiac resynchronization therapy
Study: 19339233
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg meloxicam (formulation 1)
Study: 19339233
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg meloxicam (formulation 2)
Study: 22795204
Drug: ABT-089 40
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-089 40 mg once daily
Study: 22795204
Drug: ABT-089 80
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-089 80 mg once daily
Study: 12447010
Drug: Didanosine EC
Normalized name: didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine EC (400 mg once daily), Stavudine (40 mg twice daily), Nelfinavir (750 mg three times daily)
Study: 12447010
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg twice daily) plus Lamivudine (150 mg twice daily) and Nelfinavir (750 mg three times daily)
Study: 7638372
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 50 micrograms twice daily
Study: 7638372
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 20 mg four times daily
Study: 2797637
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (50-100 micrograms every hour)
Study: 2797637
Drug: Meperidine (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (25-50 mg every 2-3 hours)
Study: 23983082
Drug: NURTURE intervention
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NURTURE intervention (weekly for 16 sessions, 1.5 hours each)
Study: 22380529
Drug: LAR 30
Normalized name: Signifor LAR 30 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAR 30 mg
Study: 22380529
Drug: LAR 10
Normalized name: Tubigrip Tubular 10m Roll
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAR 10 mg
Study: 22380529
Drug: LAR 30
Normalized name: Signifor LAR 30 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAR 30 mg, LAR 10 mg, Saline (Control)
Study: 15023167
Drug: Tenatoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenatoprazole 40 mg (T40)
Study: 15023167
Drug: Tenatoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenatoprazole 20 mg (T20)
Study: 15023167
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg (E40)
Study: 9583368
Drug: Glutamine-supplemented TPN
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-supplemented TPN (0.22 g glutamine x kg(‐1) x d(‐1) as glycyl‐glutamine)
Study: 21622587
Drug: Indacaterol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 150 μg q.d.
Study: 21622587
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 μg q.d.
Study: 18655566
Drug: E-leng Capsule
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E-leng Capsule (ELC) administered before and after operation for 3 months starting from the 7th day post-operation
Study: 18655566
Drug: Danazol administered
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol administered from the 7th day post-operation for 3 months (Control group)
Study: 18655566
Drug: E-leng Capsule
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E-leng Capsule (ELC)
Study: 16959188
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine 4 mL with 20 microg epinephrine
Study: 16959188
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine 4 mL with 40 microg epinephrine
Study: 16959188
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine 4 mL with 0 microg epinephrine
Study: 10690160
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g sucrose (859 kJ)
Study: 10690160
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g maize oil (1569 kJ)
Study: 10690160
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g sucrose, 20 g maize oil (1213 kJ)
Study: 1773870
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2 in solid gel (Cerviprost)
Study: 1773870
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2 in liquid cellulose-gel
Study: 31090511
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg SHIP1 activator
Study: 31090511
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg SHIP1 activator
Study: 21206277
Drug: Sub-Tenon lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sub-Tenon lidocaine injection (2% lidocaine)
Study: 21206277
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection (1 ml)
Study: 11788013
Drug: Pergolide therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide therapy
Study: 16353581
Drug: Clomipramine (CMI)
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine (CMI) 12.5 mg
Study: 3356082
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (325 mg) with methyldopa (500 mg)
Study: 3356082
Drug: Ferrous gluconate
Normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous gluconate (600 mg) with methyldopa (500 mg)
Study: 3356082
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (325 mg) in hypertensive subjects
Study: 27752170
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 μg/(kg×h))
Study: 24117597
Drug: Lixisenatide one-step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lixisenatide one-step dose increase
Study: 24117597
Drug: Lixisenatide two-step
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lixisenatide two-step dose increase
Study: 20308907
Drug: Propofol 200
Normalized name: propofol 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 200 mg
Study: 20308907
Drug: Propofol 350
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 350 mg
Study: 9864711
Drug: Pimozide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide (1 mg daily for 3-12 months)
Study: 6958187
Drug: Behavioural change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural change treatment programme (Section II)
Study: 6958187
Drug: Cardiologist-led treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiologist-led treatment programme (Section I)
Study: 21739158
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 2/3 of I.V. predicted carboplatin dose by I.V. infusion and the rest 1/3 as aerosol (jet nebulised D1)
Study: 21739158
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: I.V. chemotherapy (carboplatin AUC ≈ 5.5 D1)